Aβ Dynamics in LLMD

NCT05004987 | Recruiting Phase 4 DMC FDA Drug

• 1 other identifier: 21-00535
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 2

Brief Summary

This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers. The study involves an FDA-approved treatment for major depressive disorder. It will compare the SSRI antidepressant escitalopram with placebo. The hypothesis is that a reduction in depressive symptoms will be associated with a normalization of CSF AD biomarkers as well as peripheral inflammatory markers. This research would contribute to fundamental knowledge about potentially modifiable risks of Alzheimer's disease (AD).

Conditions

Alzheimer Disease; Major Depressive Disorder

Outcome Measures

Primary Outcomes (4)

• Change in Cerebrospinal Fluid (CSF) Aβ40 Biomarker Levels

  Baseline, Week 8

• Change in Cerebrospinal Fluid (CSF) Aβ42 Biomarker Levels

  Baseline, Week 8

• Change in Vascular Dysfunction (VD) Biomarker Levels

  Baseline, Week 8

• Change in Scores on Montgomery-Asberg Depression Ration Scale (MADRS)

  MADRS consists of 10 items evaluating core symptoms of depression (e.g, apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thought, and suicidal thoughts). Each symptom is rated on a 0-6 scale (0=no abnormality, 6=severe). The total score ranges from 0 to 60; the higher the score, the more severe the symptoms.

  Baseline, Week 8

Other Outcomes (3)

• Change in Plasma Aβ Biomarker Levels

  Baseline, Week 8

• Change in Cerebrospinal Fluid (CSF) P-tau Biomarker Levels

  Baseline, Week 8

• Change in Cerebrospinal Fluid (CSF) T-tau Biomarker Levels

  Baseline, Week 8

Study Arms (2)

Escitalopram (ESC)

ACTIVE COMPARATOR

Drug: Escitalopram Oxalate

Placebo (PBO)

PLACEBO COMPARATOR

Drug: Placebo

Interventions

Escitalopram Oxalate DRUG

The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.

Also known as: Lexapro, ESC

Escitalopram (ESC)

Placebo DRUG

Daily dose of placebo will mimic that of ESC.

Also known as: PBO

Placebo (PBO)

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects, age 60+ years inclusive, at the time of signing the informed consent.
• Meeting Structured Clinical Interview (SCID-5-RV) for DSM-5 criteria for Major depressive disorder.
• Montgomery-Åsberg Depression Rating Scale (MADRS) ≥18.
• Have results of a physical examination, neurological examination, vitals, and EKG within normal limits at screening.
• Cognitively unimpaired at screening visit as defined by Mini-Mental State Examination (MMSE) \>27.
• Clinical Dementia Rating Scale (CDR) Global of 0\*.
• A score of 85 or greater on the RBANS delayed memory index score.
• Fluent in English, because some of the instruments used in this study have not been translated and validated in other languages, and are able to read at a 6th grade level or equivalent, as determined by the PI.
• Medically stable with no significant cerebrovascular, neurological, or systemic disease expected to interfere with the study.
• Adequate auditory acuity and normal-to-corrected vision.
• Willing to undergo brain MRI, urine drug screen and blood sampling for routine laboratory testing, lumbar puncture, APOE genotyping and plasma drug levels.
• Only individuals with normal or non-clinically significant abnormalities on routine laboratory tests, will be included.
• If study partner is not available, the CDR will be skipped.

You may not qualify if:

• History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, or confluent (or more extensive) white matter hyperintensities.
• Mental retardation, or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
• Subjects with a Fazekas scale \>2.
• Significant history of alcoholism or drug abuse in the past 2 years. Fulfilling SCID-5-RV/DSM-5 criteria for current or past diagnosis of any psychiatric disorder (e.g., schizophrenia, bipolar disorder, or any psychotic disorder) other than recurrent MDD or anxiety disorders (e.g., panic disorder, agoraphobia, etc.).
• A current significant risk for suicidality based on the Columbia-Suicide-Severity Rating Scale (C-SSRS).
• Insulin dependent diabetes.
• Evidence of clinically relevant or unstable cardiac, pulmonary, endocrine or hematological conditions.
• Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
• Positive urine drug screen for illicit drugs.
• History of poor tolerance to, poor response to, or ongoing treatment with escitalopram.
• If taking antidepressants, currently taking fluoxetine, due to the length of time required to washout.
• Treatment with following medications will not be permitted. In some cases, medications will be allowed if medically prescribed and dose regimen stable. Note: Some medications (e.g., amphetamines, opiates) may appear on the routine urine drug test in the screening period but can be allowed as per protocol.
• For subjects taking prescribed psychoactive medications and supplements (i.e., opioids, amphetamines, amphetamine-like substances, and cannabinoids), must be on a stable dose for 1 month prior to randomization.
• Anti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine, pergolide, selegiline).
• Cholinesterase inhibitors and memantine

Sponsors & Collaborators

• NYU Langone Health: lead
• National Institute on Aging (NIA): collaborator

Study Sites (2)

NYU Langone Health

New York, New York, 10016, United States

RECRUITING

Nathan S. Kline Institute for Psychiatric Research

Orangeburg, New York, 10962, United States

RECRUITING

MeSH Terms

Conditions

Alzheimer Disease; Depressive Disorder, Major

Interventions

Escitalopram

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Depressive Disorder; Mood Disorders

Intervention Hierarchy (Ancestors)

Propylamines; Amines; Organic Chemicals; Nitriles; Benzofurans; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Nunzio Pomara, MD

  NYU Langone Health

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Antero Sarreal, MD

CONTACT

845-398-6532; Antero.sarreal@nki.rfmh.org

Chelsea Reichert Plaska, PhD

CONTACT

845-398-5583; Chelsea.reichert@nki.rfmh.org

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Both the study staff and the subjects will be blind to the study assignment.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2021
• First Posted: August 13, 2021
• Study Start: February 4, 2022
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): June 30, 2027
• Last Updated: May 6, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
• Access Criteria: The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to nunzio.pomara@nki.rfmh.org. To gain access, data requestors will need to sign a data access agreement.

Locations

US (2)